Ausgabe 5/2024
Inhalt (14 Artikel)
A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
- Open Access
- Research
Mohammad H. Ghalib, Mariano Provencio Pulla, Maria J. De Miguel Luken, Virginia Calvo de Juan, Imran Chaudhary, M Bakri Hammami, Sindhu Vikash, Radhashree Maitra, Sara Martinez, Carmen Kahatt, Sonia Extremera, Salvador Fudio, Sanjay Goel
A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants
- Open Access
- Research
Pranav Gupta, Manash Chatterjee, Yeonil Kim, Kathleen Deschamps, Lieselotte Lemoine, Kristien Van Dyck, Catherine Zhou Matthews, Sylvie Rottey, Aubrey Stoch, Eseng Lai
Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system
- Research
Chunyong Xia, Zhijing Liu, Jie Liu, Li Lin, Maohua Chen
Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis
- Research
Zhaoquan Wu, Wei Sun, Chunjiang Wang
Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery
Epiphane K. Silli, Zhenjiang Zheng, Xintao Zhou, Mengfei Li, Jiali Tang, Ruizhe Guo, Chunlu Tan, Ying Wang
Broad-spectrum anti-cancer activity of fused human arginase variants
- Research
Yenisetti Rajendra Prasad, J. Anakha, Snehal Sainath Jawalekar, Abhay H. Pande
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
- Research
Yusuke Tachibana, Kenji Morimoto, Tadaaki Yamada, Hayato Kawachi, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Taishi Harada, Koji Date, Yusuke Chihara, Isao Hasegawa, Nobuyo Tamiya, Yuki Katayama, Naoya Nishioka, Masahiro Iwasaku, Shinsaku Tokuda, Takashi Kijima, Koichi Takayama
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer
- Open Access
- Research
Shubham Pant, Byoung Chul Cho, Christos E. Kyriakopoulos, Alexander Spira, Nizar Tannir, Theresa L. Werner, Xiaohong Yan, Saskia Neuteboom, Richard Chao, Sanjay Goel
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma
- Research
Nami Mori, Nobuharu Tamaki, Shintaro Takaki, Keiji Tsuji, Toshifumi Tada, Shinichiro Nakamura, Hironori Ochi, Toshie Mashiba, Masao Doisaki, Hiroyuki Marusawa, Haruhiko Kobashi, Hideki Fujii, Chikara Ogawa, Michiko Nonogi, Hirotaka Arai, Yasushi Uchida, Naohito Urawa, Ryoichi Narita, Takehiro Akahane, Masahiko Kondo, Yutaka Yasui, Kaoru Tsuchiya, Namiki Izumi, Masayuki Kurosaki
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer
- Research
Elisabeth I. Heath, Wei Chen, Lance Heilbrun, Jae E. Choi, Kimberlee Dobson, Melanie Smith, Tomasz Maj, Ulka Vaishampayan, Ilona Kryczek, Weiping Zou, Arul M. Chinnaiyan, Yuanyuan Qiao
Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia
- Research
Liping Peng, Zhaoquan Wu, Wei Sun, Chunjiang Wang
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors
- Open Access
- Research
Nehal J. Lakhani, Howard Burris III, Wilson H. Miller Jr., Mo Huang, Lin-Chi Chen, Lillian L. Siu
Advancements of prodrug technologies for enhanced drug selectivity in pharmacotherapies
- Review
Helin Li, Wenjing Zhang, Qiu Meng, Qi Shuai
Retraction Note: The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells
- Retraction Note
Francesca De Iuliis, Ludovica Taglieri, Gerardo Salerno, Anna Giuffrida, Bernardina Milana, Sabrina Giantulli, Simone Carradori, Ida Silvestri, Susanna Scarpa
